Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GSK
GSK PLC
NYSE
$50.82
▲ UP 1.09% (0.55)

KEY STATISTICS

Market Cap$101.82 B
52w High$61.70
52w Low$38.63
Dividend Yield3.50%
FrequencyQuarterly
P/E10.98
Volume3.43M
Shares Out.2.00B

COMPANY

LEADERSHIP

Luke Victor Miels
CHIEF EXECUTIVE
Luke Victor Miels

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 28, 1980
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
66,841

PRICE TARGET

Target High$85.00
Target Low$35.25
Target Median$53.00
Target Consensus$52.45

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.$11.88B
OCT
28
WED

SPLIT RECORD

DATETYPERATIO
2022-07-22Reverse4:5
2022-07-19Reverse4:5
1991-11-12Forward2:1
1986-01-27Forward2:1
1983-02-22Forward2:1
1980-02-13Forward2:1

PRICE

$50.82 ▲ UP 1.09% (+$0.55)
OVERLAYS
$50.10$50.40$50.709:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM50.82

About GSK plc

https://www.gsk.com ↗

GSK plc, founded in 1715 and headquartered in the UK, develops vaccines and medicines across various therapeutic areas through R&D and collaborations, serving global markets.

INDUSTRY

Drug Manufacturers - General

A PRODUCT GSK PLC IS KNOWN FOR

Arexvy
Arexvy

Arexvy is a blockbuster RSV vaccine for older adults, quickly capturing U.S. market share and highlighting GSK's focus on infectious diseases and high-growth specialty medicines.

COMPETITORS

COMPETITOR
AZN COMPARE
MRNA COMPARE
PFE COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTFY2021FY2022
New And Speciality$9.97B —
Sub Total— $8.96B

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
UNITED STATES$14.54B $15.82B ▲$16.38B ▲—
Rest Of World$14.09B $13.81B ▼$14.28B ▲—
International— — — $8.28B
Europe— — — $6.85B

ETFS HOLDING THIS STOCK

ETFS HOLDING
66
LISTED HERE
26
RANKED BY POSITION SIZE
SPDW
0.29% · 4.9M
AVDE
0.37% · 1.4M
FENI
0.50% · 1.1M
PPH
4.06% · 828.9K
AFTY
1.80% · 780.9K
FVD
0.41% · 663.7K
GMOI
2.30% · 314.6K
RODM
0.82% · 269.9K
BINV
1.76% · 185.6K
CBUF.F
0.24% · 103.3K
JHMD
0.27% · 102.7K
KE
KEAT
3.49% · 85.5K
NTSI
0.43% · 83.1K
APIE
0.32% · 73.1K
DM
DMRI
0.55% · 52.1K
FLQD
2.02% · 28.4K
LST
0.64% · 22.9K
SPWO
0.50% · 22.1K
DIVY
3.21% · 18.7K
AADR
2.41% · 18.4K
GINX
0.72% · 11.6K
DIVD
2.09% · 9.8K
MEDX
2.63% · 8.9K
XGEN.L
3.18% · 7.5K
SILX
0.76% · 3.9K
HVAL
0.02% · 3.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
15.09%
HOLDERS
1,541
TOP 12 OF 1,541 · RANKED BY POSITION SIZE
Dodge & Cox
78.4M sh · $3.38B
Fmr LLC
67.7M sh · $3.73B
Fisher Asset Management, LLC
35.7M sh · $1.87B
Primecap Management Co/Ca/
25.8M sh · $1.11B
Rbc Cees Trustee Ltd
18.2M sh · $720.66M
Jtc Employer Solutions Trustee Ltd
14.6M sh · $629.94M
Wellington Management Group Llp
12.6M sh · $615.82M
Acadian Asset Management LLC
11.8M sh · $651.03M
Morgan Stanley
11.0M sh · $608.78M
Goldman Sachs Group Inc
9.6M sh · $529.22M
Royal Bank Of Canada
8.8M sh · $380.83M
Holocene Advisors, LP
8.1M sh · $398.03M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Valerie Hoyle
Valerie Hoyle
Sale (Full)
2025-09-23
 Lisa McClain
Lisa McClain
Purchase
2025-08-04
 Robert B. Aderholt
Robert B. Aderholt
Sale
2025-07-28
 Bruce Westerman
Bruce Westerman
Sale
2025-04-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
UNDERWEIGHT 1
1 GRADES IN THE LAST 12 MONTHS
Barclays UNDERWEIGHT

SECTORS PEERS

PEERPRICE
VRTX$541.69COMPARE
BMY$66.58COMPARE
CVS$93.06COMPARE
SNY$44.82COMPARE
MCK$893.39COMPARE
HCA$417.82COMPARE
ELV$394.43COMPARE
CI$278.88COMPARE